Zobrazeno 1 - 5
of 5
pro vyhledávání: '"B Serna Serrano"'
Autor:
B Serna Serrano, M Diaz Rangel, S Ruiz Sánchez, S Plata Paniagua, I Casas Hidalgo, F Sánchez Rubio, M Clemente Andújar, A Valladolid Walsh
Publikováno v:
Section 4: Clinical pharmacy services.
Background and importance Ibrutinib is a potent Burton tyrosine kinase inhibitor involved in the proliferation and survival of chronic lymphatic leukaemia (CLL) B cells. This study was mainly motivated by suspensions for toxicity. Aim and objectives
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::58f32f7e00c13f22ec1296c8778844f7
https://doi.org/10.1136/ejhpharm-2021-eahpconf.124
https://doi.org/10.1136/ejhpharm-2021-eahpconf.124
Autor:
H Alabort Ayllón, J Marco del Rio, J. M. Collado Sanz, JL Sánchez Serrano, M Sáez Garrido, B Serna Serrano, C Del Pozo Carlavilla, S Ruiz Sánchez, E Tebar Martínez, C García Gómez
Publikováno v:
Section 4: Clinical pharmacy services.
Background and importance Baricitinib is an immunosuppressive agent included as one of the therapeutic options for COVID-19 in the Spanish protocol Agencia Espanola del Medicamento y Productos Sanitarios. Aim and objectives The objective was to asses
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7e16f9f0c613d342530e8a44dc42c937
https://doi.org/10.1136/ejhpharm-2021-eahpconf.145
https://doi.org/10.1136/ejhpharm-2021-eahpconf.145
Autor:
S Plata Paniagua, E Tebar Martínez, H Alabort Ayllón, M Del Pozo Carlavilla, M Sáez Garrido, M Clemente Andújar, S Ruiz Sánchez, J. M. Collado Sanz, B Serna Serrano, C Del Pozo Carlavilla
Publikováno v:
Section 4: Clinical pharmacy services.
Background and importance Tocilizumab (TCZ) is an immunosuppressor drug, IL-6 inhibitor, indicated for the treatment of rheumatoid arthritis and cytokine release syndrome associated with CAR T cell therapy. It was proposed as a compassionate treatmen
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::15d9c182bbf7d34331eea0fbca09ac21
https://doi.org/10.1136/ejhpharm-2021-eahpconf.164
https://doi.org/10.1136/ejhpharm-2021-eahpconf.164
Autor:
M Clemente Andújar, B Serna Serrano, S Ruiz Sánchez, H Alabort Ayllón, C Del Pozo Carlavilla, M Sáez Garrido, S Plata Paniagua, E Tebar Martínez, M Del Pozo Carlavilla, CS Juan Manuel
Publikováno v:
Section 4: Clinical pharmacy services.
Background and importance Tocilizumab (TCZ) is an immunosuppressor drug, IL-6 inhibitor, indicated for the treatment of rheumatoid arthritis and cytokine release syndrome associated with CAR T cell therapy It was proposed as a compassionate treatment
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::77f7a4e587592c9385f96ae1d60b440a
https://doi.org/10.1136/ejhpharm-2021-eahpconf.163
https://doi.org/10.1136/ejhpharm-2021-eahpconf.163
Autor:
A Valladolid Walsh, A Serrano Martínez, I Pérez Alpuente, V Lerma Gaude, B Serna Serrano, M Clemente Andújar, R. Aldaz Francés
Publikováno v:
Section 5: Patient safety and quality assurance.
Background and importance Fidaxomicin is a macrolide antibiotic used to treat intestinal Clostridium difficile (CD) infection in the absence of metronidazole or vancomycin treatments. Pharmacovigilance collects information, and analyses and notifies
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0976c9a6c79756bc4ff1ffbc47547380
https://doi.org/10.1136/ejhpharm-2021-eahpconf.240
https://doi.org/10.1136/ejhpharm-2021-eahpconf.240